ArticlePloS one2014
Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- Preeclampsia and Onset of Renal Disorders in the Long-Term Period following Pregnancy.American journal of nephrology · 2026Article
- Podocytopathies.Nature reviews. Disease primers · 2025Review
- Podocyturia an emerging biomarker for kidney injury.BMC nephrology · 2025Review
- Urinary podocyte markers of disease activity, therapeutic efficacy, and long-term outcomes in acute and chronic kidney diseases.Clinical and experimental nephrology · 2024Review
- Relationship between parity and the prevalence of chronic kidney disease in Japan considering hypertensive disorders of pregnancy and body mass index.BMC nephrology · 2024Article
- History of Preeclampsia in Patients Undergoing a Kidney Biopsy: A Biphasic, Multiple-Hit Pathogenic Hypothesis.Kidney international reports · 2022Article
- Angiotensin II type 1 receptor agonistic autoantibody blockade improves postpartum hypertension and cardiac mitochondrial function in rat model of preeclampsia.Biology of sex differences · 2021Article
- Preeclampsia and Kidney Disease: Deciphering Cause and Effect.Current hypertension reports · 2020Review
- Preeclampsia and risk of end stage kidney disease: A Swedish nationwide cohort study.PLoS medicine · 2019Observational
- Reply to: Acute kidney injury in parturients with severe preeclampsia.Journal of anesthesia · 2018Article
- Risk of cardiovascular disease, end-stage renal disease, and stroke in postpartum women and their fetuses after a hypertensive pregnancy.American journal of physiology. Regulatory, integrative and comparative physiology · 2018Review
- Vascular Dysfunction in Mother and Offspring During Preeclampsia: Contributions from Latin-American Countries.Current hypertension reports · 2017Review
- Podocytes from the diagnostic and therapeutic point of view.Pflugers Archiv : European journal of physiology · 2017Review
- Preeclampsia and ESRD: The Role of Shared Risk Factors.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Article
- A best practice position statement on pregnancy in chronic kidney disease: the Italian Study Group on Kidney and Pregnancy.Journal of nephrology · 2016Review
- Urinary Podocyte Loss Is Increased in Patients with Fabry Disease and Correlates with Clinical Severity of Fabry Nephropathy.PloS one · 2016Article
- Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism.American journal of nephrology · 2016Article
- From Glomerular Endothelium to Podocyte Pathobiology in Preeclampsia: a Paradigm Shift.Current hypertension reports · 2015Review
- Is It Possible to Differentiate Chronic Kidney Disease and Preeclampsia by means of New and Old Biomarkers? A Prospective Study.Disease markers · 2015Article
- Hypertensive pregnancy disorders and future renal disease.Current hypertension reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectiveStudies have shown that podocyturia, i.e., urinary loss of viable podocytes (glomerular epithelial cells), is associated with proteinuria in preeclampsia. We postulated that urinary podocyte loss may persist after preeclamptic pregnancies, thus resulting in renal injury. This may lead to future chronic renal injury. In addition, we compared the postpartum levels of the angiogenic factors, which previously have been associated with preeclampsia, between normotensive versus preeclamptic pregnancies. STUDY
designThe diagnosis of preeclampsia was confirmed using standard clinical criteria. Random blood and urine samples were obtained within 24 hours prior to delivery and 5 to 8 weeks postpartum. Urine sediments were cultured for 24 hours to select for viable cells and staining for podocin was used to identify podocytes. Serum samples were analyzed for the levels of angiogenic markers using ELISA (enzyme-linked immunosorbent assay) methodology.
resultsAt delivery, preeclamptic patients (n = 10) had significantly higher proteinuria (p = 0.006) and podocyturia (p<0.001) than normotensive pregnant patients (n = 18). Postpartum proteinuria was similar between these two groups (p = 0.37), while podocyturia was present in 3 of 10 women with preeclampsia and in none of the normotensive controls (p = 0.037). Angiogenic marker levels, including placental growth factor, soluble vascular endothelial growth factor receptor fms-like tyrosine kinase receptor-1 and endoglin, were not significantly different between women with preeclampsia and women with a normotensive pregnancy, either at delivery or postpartum.
conclusionPersistent urinary podocyte loss after preeclamptic pregnancies may constitute a marker of ongoing, subclinical renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.